Article Sidebar
Published:
Jul 10, 2013Keywords:
Neuroprotection Glaucoma.
Article Details
Issue
Section
Articles
The Journal is owned, published, and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. Open access authors retain the copyrights of their papers, with the work three months after publication simultaneously licensed under a Creative Commons Attribution License (Attribution, Non-Commercial, No Derivatives” 4.0) - (CC BY-NC-ND 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Main Article Content
Neuroprotection in Glaucoma: A Review
Abstract
Background: Glaucoma, globally the second most common cause of blindness and the commonest cause of preventable visual disability, is a progressive neurodegenerative disease of the retinal ganglion cells and their axons .Neuroprotection is an evolving area in the management of glaucoma. This review aims to highlight the current neuroprotective agents under investigation and the promise they hold for future management of glaucoma.
Method: The available literature on the use of Neuroprotection in Glaucoma was reviewed using available journals and internet based search engines such as pubmed and Medline. Keywords employed were Neuroprotection and Glaucoma.
Results: There is ongoing research on neuroprotective agents in management of glaucoma. A few of the currently available anti glaucoma medications also have neuroprotective functions. The mainstay of glaucoma management however remains lowering of intraocular pressure. Nigerian literature on neuroprotection was not available.
Conclusion: It has become increasingly obvious that glaucoma represents a complex multifactorial disease that produces an accelerated rate of ganglion cell atrophy related to a numerous pathogenic mechanisms that not only most certainly involve IOP, but also include defective auto regulation and ischaemia; neurotrophic factor deficiency; glutamate mediated excitotoxicity, immune related phenomenon; intracellular calcium influx and free 3 radical damage. IOP lowering still remains the mainstay of treatment. Neuroprotection has promise for preventing retinal cell ganglion death independent of IOP. It therefore presents an exciting development in the pursuit for a treatment modality for this debilitating disease.
Keywords: Neuroprotection; Glaucoma.
Method: The available literature on the use of Neuroprotection in Glaucoma was reviewed using available journals and internet based search engines such as pubmed and Medline. Keywords employed were Neuroprotection and Glaucoma.
Results: There is ongoing research on neuroprotective agents in management of glaucoma. A few of the currently available anti glaucoma medications also have neuroprotective functions. The mainstay of glaucoma management however remains lowering of intraocular pressure. Nigerian literature on neuroprotection was not available.
Conclusion: It has become increasingly obvious that glaucoma represents a complex multifactorial disease that produces an accelerated rate of ganglion cell atrophy related to a numerous pathogenic mechanisms that not only most certainly involve IOP, but also include defective auto regulation and ischaemia; neurotrophic factor deficiency; glutamate mediated excitotoxicity, immune related phenomenon; intracellular calcium influx and free 3 radical damage. IOP lowering still remains the mainstay of treatment. Neuroprotection has promise for preventing retinal cell ganglion death independent of IOP. It therefore presents an exciting development in the pursuit for a treatment modality for this debilitating disease.
Keywords: Neuroprotection; Glaucoma.
